A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination With Ipilimumab in Participants With Advanced Malignancies
A study to evaluate the safety of Nivolumab administered in combination with Ipilimumab in
patients with advanced cancers. The initial cohort will enroll patients with newly diagnosed
Stage 4 or recurrent non-small cell lung cancer.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society